| Realtime | Geld | Brief | Zeit |
|---|---|---|---|
| 2,120 | 2,140 | 12:36 |
| Zeit | Aktuelle Nachrichten Sprache:
Alle DE EN | Leser | Medien | ||
|---|---|---|---|---|---|
| HEALIOS Aktie jetzt für 0€ handeln |
| Unternehmen / Aktien | Aktienkurs | % | Top-Nachrichten | ||
|---|---|---|---|---|---|
| DAY ONE BIOPHARMACEUTICALS | 21,380 | +0,09 % | Weekly Buzz: Bristol Myers Squibb Wins FDA Nod; EU Okays Johnson & Johnson's AKEEGA; Ipsen Withdraws Tazverik, Day One Biopharmaceuticals Acquired | NEW BRUNSWICK (dpa-AFX) - This week's biotech landscape witnessed key FDA approvals, EU approvals, IND clearances, acquisitions, and clinical trial data readouts across key therapeutic areas... ► Artikel lesen | |
| ADMA BIOLOGICS | 11,330 | 0,00 % | ADMA Biologics, Inc.: ADMA Biologics Addresses Misleading Short-Seller Report | RAMSEY, N.J. and BOCA RATON, Fla., March 25, 2026 (GLOBE NEWSWIRE) -- ADMA Biologics, Inc. (Nasdaq: ADMA) ("ADMA" or the "Company"), a U.S. based, end-to-end commercial biopharmaceutical company dedicated... ► Artikel lesen | |
| EDGEWISE THERAPEUTICS | 30,640 | 0,00 % | Why Edgewise Therapeutics Stock Topped the Market on Tuesday | ||
| KINIKSA PHARMACEUTICALS | 44,940 | 0,00 % | Kiniksa Pharmaceuticals International, Plc: Kiniksa Pharmaceuticals Reports Fourth Quarter and Full Year 2025 Financial Results and Recent Portfolio Execution | - ARCALYST- (rilonacept) Q4 2025 and full year 2025 net product revenue of $202.1 million and $677.6 million, respectively -- ARCALYST 2026 net product revenue expected to be $900 - $920 million... ► Artikel lesen | |
| VIR BIOTECHNOLOGY | 8,570 | 0,00 % | Vir Biotechnology +70%: Deal-Überraschung mit Ansage | Die Aktie von Vir Biotechnology ist vorbörslich um rund 70 Prozent nach oben geschossen. Auslöser der Kursexplosion ist vor allem ein milliardenschwerer Kooperationsdeal mit dem japanischen Pharmakonzern... ► Artikel lesen | |
| ARCELLX | 114,66 | 0,00 % | Arcellx legt Zahlen vor - Augenmerk liegt auf Gilead-Übernahme | ||
| APOGEE THERAPEUTICS | 72,98 | 0,00 % | Morning Market Movers: urban-gro, WeShop Holdings, QVC Group, Apogee Therapeutics See Big Swings | OTTAWA (dpa-AFX) - At 8:30 a.m. ET on Monday, premarket trading is seeing notable activity in several stocks, with early price movements signaling potential opportunities before the opening... ► Artikel lesen | |
| QIAGEN | 34,920 | +1,32 % | QIAGEN N.V.: Qiagen Announces Form 20-F Annual Report Filing for 2025 Results | QIAGEN N.V. (NYSE: QGEN; Frankfurt Prime Standard: QIA) announced today that it has filed its annual report, including its audited consolidated financial statements on Form 20-F, for the year ended... ► Artikel lesen | |
| PHATHOM PHARMACEUTICALS | 10,060 | 0,00 % | Phathom Pharmaceuticals Announces Preliminary Fourth Quarter and Full Year 2025 Financial Results | FLORHAM PARK, N.J., Jan. 07, 2026 (GLOBE NEWSWIRE) -- Phathom Pharmaceuticals, Inc. (Nasdaq: PHAT), a biopharmaceutical company focused on developing and commercializing novel treatments for gastrointestinal... ► Artikel lesen | |
| CONTINEUM THERAPEUTICS | 12,330 | 0,00 % | Stifel reiterates Buy on Contineum stock, keeps $29 price target | ||
| BIONTECH | 76,05 | +1,13 % | Euphorie und Panik liegt dicht beisammen! BioNTech, Globex Mining, SAP | Die Finanzmärkte sind seit dem Iran-Krieg deutlich angeschlagen und nur die Hoffnung auf einen möglichen zeitnahen Frieden lässt die Märkte in dieser Woche wieder stabilisieren. Doch die Hoffnung ist... ► Artikel lesen | |
| TANGO THERAPEUTICS | 19,480 | 0,00 % | Erasca, Inc.: Erasca and Tango Therapeutics Enter into Clinical Collaboration to Evaluate Combination of ERAS-0015 and Vopimetostat | ERAS-0015, a pan-RAS molecular glue, will be evaluated in combination with PRMT5 inhibitor vopimetostat Tango will sponsor the clinical trial and Erasca will supply ERAS-0015 at no cost SAN DIEGO... ► Artikel lesen | |
| ERASCA | 14,645 | 0,00 % | Erasca (ERAS) Adds 13%; Soars 310% YTD | ||
| EVOTEC | 4,360 | +5,85 % | Welche Aktie jetzt kaufen? Evotec, Nel und Lahontan Gold. | Was ist denn da bei Nel los? Innerhalb weniger Tage hat die einstige Wasserstoffhoffnung über 20 % an Wert gewonnen. Der kurzfristige Abwärtstrend wurde verlassen. Doch Analysten sehen keine Trendwende.... ► Artikel lesen | |
| LENZ THERAPEUTICS | 9,010 | 0,00 % | LENZ Therapeutics, Inc.: LENZ Therapeutics Reports Fourth Quarter and Full Year 2025 Financial Results and Recent Corporate Highlights | Launched VIZZ- (aceclidine ophthalmic solution) 1.44% for the treatment of presbyopia in October 2025 and generated net product revenues of $1.6 million in the first quarter of launch On pace for... ► Artikel lesen |